Everolimus with reduced CsA vs MMF with standard CsA exposure in de novo heart transplant recipients: 12 Month efficacy and safety analysis

Category Primary study
JournalJournal of Heart and Lung Transplantation
Year 2011
This article has no abstract
Epistemonikos ID: 64bdf573a40249a4f081c96ee339e2904f740923
First added on: Feb 04, 2025